Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Rhythm Biosciences Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19M | 3.19M | 1.69M | 3.10M | 2.43M | 1.11M |
| Gross Profit | 372.04K | 2.97M | -1.36M | 2.91M | -101.48K | 961.86K |
| EBITDA | -3.53M | -3.53M | -8.35M | -11.11M | -11.10M | -6.46M |
| Net Income | -3.83M | -3.83M | -6.86M | -8.22M | -8.79M | -6.61M |
Balance Sheet | ||||||
| Total Assets | 2.83M | 2.83M | 1.52M | 7.70M | 8.44M | 3.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.48M | 1.48M | 754.50K | 4.17M | 7.60M | 2.27M |
| Total Debt | 1.11M | 1.11M | 163.82K | 84.61K | 170.14K | 0.00 |
| Total Liabilities | 2.17M | 2.17M | 651.54K | 1.82M | 1.07M | 1.36M |
| Stockholders Equity | 659.89K | 659.89K | 867.17K | 5.87M | 7.37M | 1.71M |
Cash Flow | ||||||
| Free Cash Flow | -2.94M | -2.94M | -6.22M | -7.06M | -6.24M | -5.47M |
| Operating Cash Flow | -2.92M | -2.92M | -6.14M | -6.96M | -6.21M | -5.40M |
| Investing Cash Flow | -582.96K | -582.96K | -82.28K | -99.12K | -27.01K | -68.27K |
| Financing Cash Flow | 4.19M | 4.19M | 2.80M | 3.63M | 11.85M | 5.90M |
Rhythm Biosciences Ltd. Technical Analysis
Rhythm Biosciences Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$46.01M | -5.81 | -97.79% | ― | ― | 23.85% | |
45 Neutral | AU$182.26M | -12.73 | -111.23% | ― | 12.96% | 40.81% | |
44 Neutral | AU$50.59M | -10.85 | -501.54% | ― | ― | 56.42% | |
43 Neutral | AU$5.67M | -0.55 | ― | ― | -56.35% | 42.80% | |
40 Underperform | AU$40.88M | -1.88 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$53.49M | -5.94 | -37.78% | ― | 2.33% | 12.50% |
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences has issued 1,000,000 new ordinary shares on 16 January 2026 and has lodged a cleansing notice confirming that the shares were issued without a prospectus under the Corporations Act disclosure exemptions. The company states it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information requiring disclosure, providing investors with assurance around regulatory compliance as it continues to advance and commercialise its cancer diagnostics offerings, including its ColoSTAT colorectal cancer blood test.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has applied to the ASX for quotation of 1,000,000 new ordinary fully paid shares, with an issue date of 16 January 2026. The additional securities, issued under a previously announced transaction, will expand the company’s listed share base and may modestly increase liquidity for existing and new investors.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has disclosed the cessation of 750,000 fully paid ordinary employee performance rights (ASX code: RHYAR), which lapsed after the conditions attached to those rights were not met or became incapable of being satisfied as of 13 January 2026. The lapse reduces the pool of potential future share issuances tied to employee incentives, modestly tightening the company’s prospective capital base and reflecting adjustments to its employee equity scheme without impacting existing shareholders’ current holdings.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has commercially launched an enhanced version of its geneType colorectal cancer risk assessment test, which now integrates genetic, clinical and lifestyle factors, along with gender-specific variables, to deliver improved risk stratification across both men and women, including younger adults. Backed by peer-reviewed validation showing stronger performance than traditional models, the upgraded test is intended to identify a broader cohort of higher-risk individuals earlier, support more targeted screening pathways and boost participation in bowel cancer screening programs, while also creating a complementary funnel for the company’s ColoSTAT blood-based colorectal cancer detection test and strengthening its positioning in predictive oncology and early detection markets.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has issued 31,250 unquoted options under an employee incentive scheme, with each option exercisable at A$0.20 and expiring on 30 November 2027, as notified in an Appendix 3G filing to the ASX. The move underscores the company’s ongoing use of equity-based incentives to attract and retain key staff, aligning employee interests with shareholders and potentially modestly increasing the company’s fully diluted capital base if the options are exercised.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences has notified the ASX of a proposed issue of up to 625,000 ordinary fully paid shares under a placement or similar capital-raising mechanism, with the new securities expected to be issued on 2 February 2026. The move signals an intention to bolster the company’s capital base, which may support ongoing operations and development activities, and could modestly dilute existing shareholders while potentially strengthening Rhythm’s financial position ahead of future milestones.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has announced a proposed issuance of up to 1,000,000 fully paid ordinary securities, with a scheduled issue date of January 30, 2026. This strategic move could provide the company with additional capital to support its ongoing development efforts and strengthen its positioning in the competitive biotechnology industry.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has initiated the commercialization of its ColoSTAT® test, a blood-based diagnostic tool for colorectal cancer, following an updated ISO15189:2022 accreditation. This marks a significant milestone as ColoSTAT® addresses the unmet clinical need for patients where stool-based testing is unsuitable or not preferred. The test will be rolled out through Rhythm’s certified laboratory in Melbourne, with immediate domestic market activities. The company plans to conduct a variation to scope assessment with the National Association of Testing Authorities in January 2026, which would further establish ColoSTAT® as an accredited laboratory service, enhancing clinician confidence and commercial scalability.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd announced the departure of its Chief Financial Officer, Mr. Todd Perkinson, effective December 19, 2025. This change in leadership comes as the company continues to focus on its mission of providing innovative diagnostic solutions for early cancer detection. The departure could impact the company’s financial strategy and operations, but the board expressed gratitude for Mr. Perkinson’s contributions.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has announced a collaboration with the NHS Southern Hub Research Team to evaluate its ColoSTAT® blood-based test for bowel cancer screening in England. This evaluation is a significant step towards the international commercialization of ColoSTAT®, which could enhance Rhythm’s market positioning by potentially reducing colorectal cancer mortality and healthcare costs.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has entered into a marketing partnership with Catch Bio, a cancer prevention platform, to introduce its geneTypeTM Cancer Risk Assessment Test to Catch Bio’s US member base. This collaboration enhances Catch Bio’s platform by integrating Rhythm’s clinically validated polygenic risk assessment for multiple cancers, supporting Rhythm’s US market expansion strategy. The partnership signifies a commercial milestone for Rhythm, reflecting growing market acceptance of geneTypeTM and expanding its presence in a key global market. The integration of geneTypeTM with Catch Bio’s AI-driven risk model offers a comprehensive risk profile for proactive cancer prevention, marking a significant step in Rhythm’s commitment to early cancer detection.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. has announced a change in the director’s interest notice, specifically concerning David Atkins. The update details the acquisition of various securities, including ordinary shares, loan-funded shares, listed options, unlisted options, and deferred shares, following approval at the Annual General Meeting. This change reflects a strategic adjustment in the company’s governance and may influence its market perception and stakeholder confidence.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced a change in the director’s interest, with Gavin Fox-Smith acquiring a significant number of securities, including ordinary shares and options. This acquisition, approved at the Annual General Meeting, reflects strategic moves within the company to align leadership interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced a change in the director’s interest, with Sue MacLeman acquiring 450,000 loan funded shares and 450,000 unlisted options, while disposing of 200,000 unlisted options. This change, approved by shareholders at the Annual General Meeting, reflects a strategic adjustment in the company’s governance and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced the cessation of 200,000 securities due to the lapse of conditional rights, as the conditions were not met by the expiration date of November 30, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced the issuance of 2,700,000 unquoted equity securities in the form of options expiring on November 30, 2027, with an exercise price of $0.20. This issuance, part of an employee incentive scheme, reflects the company’s strategic efforts to align employee interests with long-term growth objectives, potentially impacting its operational dynamics and market positioning.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd announced the issuance of 3,333,332 ordinary shares without disclosure under Part 6D.2 of the Corporations Act. The company confirmed compliance with relevant provisions of the Corporations Act and stated there is no excluded information to disclose. This move supports Rhythm’s ongoing efforts in enhancing its financial position to further develop and distribute its diagnostic products, potentially impacting its market presence positively.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced the issuance of unquoted equity securities, specifically options expiring in 2027 and 2028. This move is part of an employee incentive scheme and is not intended for public trading on the ASX, indicating a strategy to motivate and retain key personnel. The issuance of these options could potentially enhance the company’s operational capabilities by aligning employee interests with long-term company goals.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd. announced the issuance of 2,193,001 unquoted equity securities under an employee incentive scheme. This move is part of the company’s strategy to incentivize and retain talent, potentially enhancing its operational capabilities and competitive positioning in the biotechnology sector.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has released a report detailing the holdings of its listed options, which are set to expire on November 30, 2027. The report indicates that a significant portion of the options, 96.67%, is held by a small group of 67 holders, with the top holder being HSBC Custody Nominees (Australia) Limited, owning 10.06% of the issued share capital. This concentration of holdings could have implications for the company’s market dynamics and investor relations, as it suggests a limited distribution of shares among a few stakeholders.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd has successfully transitioned its geneType™ Laboratory to the ISO 15189:2022 standard, securing updated accreditation. This achievement allows Rhythm to continue delivering its geneType™ risk assessment service and positions the company to commercialize its ColoSTAT® test as an in-house IVD, pending further assessment. The transition will also help optimize operational costs by eliminating the need for ISO13485 status. This strategic move strengthens Rhythm’s laboratory systems and supports a unified commercial strategy for its products, enhancing market access and operational efficiency.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Ltd announced the independent validation of its geneType Ovarian Cancer Risk Prediction Model through the Nurses’ Health Study, confirming its ability to identify twice as many women at elevated risk compared to clinical models alone. This validation supports the model’s clinical utility and aligns with the company’s strategy to enhance personalized and proactive disease management, potentially impacting early detection and prevention strategies in healthcare.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
Rhythm Biosciences Limited has released a presentation for general informational purposes, emphasizing that the information provided is not intended as investment advice and may be subject to change. The company highlights that the presentation includes forward-looking statements, which are predictions subject to risks and uncertainties, and advises recipients not to rely on these statements for investment decisions.
Rhythm Biosciences Ltd announced the receipt of a $1.571 million Research and Development Tax Incentive and the repayment of a $1 million loan from Endpoints Capital. The company will continue to participate in the Australian Government’s R&D incentive program, which supports its ongoing research efforts. This financial maneuver strengthens Rhythm’s position in the cancer diagnostics industry, allowing it to focus on its mission of early cancer detection and potentially impacting healthcare costs and patient outcomes positively.
Rhythm Biosciences Ltd. has announced a change in its board of directors, with Otto Buttula ceasing to be a director as of November 5, 2025. This change in leadership may impact the company’s strategic direction and stakeholder interests, as it involves significant holdings in the company through various investment entities.
Rhythm Biosciences Ltd announced that all resolutions at its Annual General Meeting were passed by poll, reflecting strong shareholder support. This outcome signifies confidence in the company’s strategic direction and ongoing initiatives, potentially strengthening its position in the medical diagnostics industry.
Rhythm Biosciences Ltd has appointed Gavin Fox-Smith as the new Chair following the retirement of Otto Buttula. This leadership change marks a new phase for the company, which is known for its innovative cancer diagnostics technology. The transition is expected to support the company’s growth and enhance shareholder value as it continues to develop its cancer detection solutions.
Rhythm Biosciences Ltd. presented a post-AGM update, highlighting ongoing investigations and potential changes in their projects. The presentation underscores the company’s commitment to advancing its research, though it cautions stakeholders about the uncertainties and risks involved, which may impact future operations and market positioning.
Rhythm Biosciences Ltd announced the successful evaluation of its ColoSTAT® test, which demonstrates consistent performance in detecting colorectal cancer across various age groups and genders. The test shows promise for early onset cancer detection in patients under 50 years old, addressing a growing need in the healthcare industry. The company plans further studies to establish statistical significance and aims for commercial release following regulatory assessments.
Rhythm Biosciences Ltd has announced significant progress in its operations for the first quarter of FY26, highlighted by strategic distribution partnerships for its Genetype product and advancements in the commercial readiness of its ColoSTAT® kits. The company has also successfully raised $3.75 million in capital, indicating strong investor confidence. These developments position Rhythm Biosciences to achieve its strategic objectives for the year, with a focus on commercializing ColoSTAT® and expanding its product offerings.